Berkeley Lights Releases Upgrade to its Software Suite for Beacon® and Lightning™ Platforms
Scientific researchers can now more easily assess cell and assay quality in real-time by selecting the best individual cells for live export
EMERYVILLE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI) a leader in digital cell biology, today released an upgrade to its Software Suite including enhancements to Cell Analysis Suite (CAS™), Image Analyzer, and Assay Analyzer software for the Berkeley Lights Beacon and Lightning Systems. Existing and new features will deliver easier insights, faster throughput operations for antibody discovery, cell line development and cell therapy workflows.
“Our new software releases are already helping upgraded Berkeley Lights Platform customers make advanced discoveries, rapidly and efficiently,” said Mimi Healy, Ph.D., chief product officer of Berkeley Lights. “Developed in response to ‘voice of the customer’ initiatives and feedback from our dedicated field service teams, the upgrade focuses on three key features to enhance the scientific process—including the ability to conserve more precious samples with quicker loading time, faster results with more automation and intuitiveness, and refined analysis for easier data management and visualization.”
More about Berkeley Lights software
The BLI Software Suite guides users through each step of the process including instrument setup, data analysis and cell selection for export. Customers can run their workflows and analyze their results faster than before through these upgraded features:
- Precious sample recovery and re-import (available for small volume import with well import lid)
- Enhanced montage data viewing for easier and faster hit and assay scoring
- New trellis plot functionality in Image Analyzer for more in-depth analysis
- Increased functionality through new customizable workflow operations
- Refined image quality during unload for better accuracy
- Easier cleaning for more robust systems
- Greater reporting ease through use of film strips from timelapse images
- Improved timeline interface in Assay Analyzer for easier data management and visualization
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
Berkeley Lights’ Beacon® and Lightning™ systems and Culture Station™ instrument are FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its platform, components thereof such as software and products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company’s growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.
Media Contacts
Investor Contact
